Biochemist Dr. Jennifer Doudna, from the University of California, Berkeley, submitted her patent application for the core CRISPR technology back in May 2012 after creating the tech along with Emmanuelle Charpentier.
But then biologist Feng Zhang from the Broad Institute of Harvard and MIT submitted a similar patent application in 2013--but he requested a fast-track process and received the official patent in April 2014. Zhang has since been awarded additional patents on the technology.
CRISPR’s Nobel Prize winners defeated in key patent claim for genome editor
According to a ruling by an appeal board of the U.S. Patent and Trademark Office (USPTO), a different group, led by the Broad Institute of MIT and Harvard, made the “actual reduction to practice” of CRISPR’s ability to edit eukaryotic cells, including humans. This means companies developing CRISPR-based medicines must now negotiate with Broad and its partners, Harvard University and the Massachusetts Institute of Technology, for the use of the editor.
I think it goes something like this:
Doudna, et. al. were the first to discover and describe CRISPR in nature.
Zhang, et. al. were the first to successfully develop ways to edit genomes with it.
Mojica is generally considered the "discoverer of CRISPR". Douda and Charpentier took that knowledge and made a specific genome editing system based on bacterial enzymes (Cas9) and demonstrated it working in bacteria. Zhang is generally considered the person who made it work in eukaryotes.
But then biologist Feng Zhang from the Broad Institute of Harvard and MIT submitted a similar patent application in 2013--but he requested a fast-track process and received the official patent in April 2014. Zhang has since been awarded additional patents on the technology.
https://www.fiercebiotech.com/biotech/crispr-patent-battle-h...
Nobel Prize for CRISPR honors two great scientists – and leaves out many others
https://theconversation.com/nobel-prize-for-crispr-honors-tw...
CRISPR’s Nobel Prize winners defeated in key patent claim for genome editor
According to a ruling by an appeal board of the U.S. Patent and Trademark Office (USPTO), a different group, led by the Broad Institute of MIT and Harvard, made the “actual reduction to practice” of CRISPR’s ability to edit eukaryotic cells, including humans. This means companies developing CRISPR-based medicines must now negotiate with Broad and its partners, Harvard University and the Massachusetts Institute of Technology, for the use of the editor.
https://www.science.org/content/article/crispr-s-nobel-prize...